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240 Effect of exercise capacity on bone mineral density in cystic
ﬁbrosis
E. Hatziagorou1, K. Kontouli1, V. Avramidou1, F. Kirvasillis1, E. Kazantzidou2,
J.N. Tsanakas1. 1Hippokration Hospital, Aristotle University of Thessaloniki,
Paediatric Pulmonology Unit, 3rd Paediatric Dept, Thessaloniki, Greece;
2Hippokration Hospital, Radiology Dept, Thessaloniki, Greece
Aims:
1. To assess bone status in children and adolescents with CF.
2. To correlate Bone Mineral density (BMD) with exercise capacity, FEV1, physical
activity level, disease severity and BMI among CF childhood population.
Methods: Thirty-six patients with CF (mean age: 14.9, mean FEV1: 81%),
participated in the study. All patients had DEXA scan at lumbar spine vertebrae
(L2−L4). Results were expressed as Z-scores compared with sex- and age-matched
population. Questionnaires were ﬁlled in, regarding physical activity levels. All
patients performed spirometry and maximal incremental cardiopulmonary exercise
testing using a cycle ergometer (10watt ramp protocol) (Ergoline 200P, Sensor
Medics). Differences in disease severity (Shwachman–Kulczycki score, exercise
capacity, physical activity level, body mass index [BMI]) were correlated with
BMD Z-scores.
Results: The mean BMD values, serum calcium, phosphorus and parathyroid hor-
mone levels were within normal range. BMD Z-scores were 0.34±0.9 (mean±SD).
Based on a lumbar spine z-score by DEXA, 8 (22%) of the patients had osteopenia,
(−2.5< z-score<−1) and 2 (5%) had osteoporosis (z-score −2.5). There was
evidence of mild exercise limitation during the cardiopulmonary exercise test, with
mean Peak Aerobic Capacity (V′Opeak) 68.77±21.6% predicted. Multiple linear
regression identiﬁed exercise capacity [VOpeak, VD/VT (ratio of physiologic dead
space to tidal volume)], Shwachman score and BMI as signiﬁcant predictors of
BMD (p = 0.004, p = 0.03, p = 0.03, p = 0.04 respectively).
Conclusion: Limited exercise capacity, reduced BMI and disease severity are
predictors of low BMD among children and adolescents with CF.
241 Iatrogenic suppression of the hypothalamic–pituitary–adrenal
axis in cystic ﬁbrosis; a cause for concern
F.J. Gilchrist1, K.J. Cox1, R. Rowe1, A.K. Webb1, A. Jones1, R.J. Bright-Thomas1.
1Manchester Adult Cystic Fibrosis Unit, Manchester, United Kingdom
Introduction: There are reports of hypothalamic–pituitary–adrenal (HPA) axis sup-
pression caused by inhaled corticosteroids (ICS) when combined with itraconazole.
It is caused by itraconazole inhibiting the cytochrome P450 dependent CYP3A4
pathway involved in metabolising some synthetic glucocorticoids. This increases
steroid levels which negatively feedback on the HPA axis.
Methods: We performed synacthen tests in 12 patients on itraconazole and ICS
and 8 patients on ICS but not itraconazole. We excluded patients on any exogenous
source of steroids other than ICS. Itraconazole levels were also taken.
Results: 7/8 in the ICS group and 10/12 in the ICS/itraconazole group were
on ﬂuticasone. The median dose of ﬂuticasone equivalent was 500mcg/day in
both groups. All patients on ICS alone had a normal synacthen test. In the
ICS/itraconazole group only one patient reached a peak cortisol of 570 nmol/L and
2 had a rise of >200 nmol/L, no patient met both criteria. Five patients had severe
HPA axis suppression (basal cortisol <75 nmol/L and peak cortisol of <250 nmol/L).
The degree of suppression was not proportional to the itraconazole level.
Table: Synacthen test results
Cortisol level [nmol/L], median (range)
Basal 30 min Rise
ICS & itraconazole (n = 12) 171 (22–414) 373 (59–574) 179 (37–236)
ICS alone (n = 8) 352 (41–518) 674 (571–904) 383 (210–449)
Conclusions: All patients on ICS and itraconazole had HPA axis suppression and
in some this was severe. In contrast, all those on ICS alone were adrenal sufﬁcient.
Therefore, in patients with CF, treatment with a combination of ICS and itraconazole
should be avoided. If this is not possible, the dose of ICS should be reduced and
the degree of suppression monitored with a synacthen test.
242 Are we missing salt depletion in cystic ﬁbrosis?
S. Sharp1, C. Marks1, K. Chetty2, L. Jason2, P. Seddon2. 1Brighton and Sussex
Medical School, Child Health, Brighton, United Kingdom; 2Royal Alexandra
Children’s Hospital, Brighton, United Kingdom
Objectives: Salt depletion was the clinical feature which ﬁrst differentiated cystic
ﬁbrosis from coeliac disease, but in temperate climates it has not been considered a
common problem. Most guidelines do not suggest routine sodium supplementation,
few clinics screen for sodium depletion outside infancy, and there is no agreement
on the best screening measure. Public health initiatives in the general population
are leading to lower salt intakes. We planned to determine the prevalence of sodium
depletion in our clinic, as measured by three screening methods, and to compare
the sensitivity of these methods.
Methods: Urine samples were taken at annual review from 28 children (mean
age 9 years). Urinary sodium (UNa), urinary sodium:creatinine ratio (UNaCr) and
urinary sodium:potassium ratio (UNaK) were measured. If blood electrolytes were
available, fractional sodium excretion (FeNa) was also calculated. Sodium depletion
was deﬁned by UNa <20mmol/L, UNaCr <17, UNaK <2 and FeNa <0.5%.
Results: Using these criteria, sodium depletion was detected by UNa in only 4%
(1 child), but by UNaCr in 88%, UNaK in 82%, and FeNa in 77%. FeNa
correlated strongly with UNaCr and UNaK, but not with UNa. Sodium depletion
was not limited to infants and preschool children. None of the children had clinical
symptoms suggestive of sodium depletion.
Conclusions: Our results suggest that subclinical sodium depletion may be com-
mon across the age range in children with CF, and that simple urinary sodium
concentration is an insensitive screening test. Further work is needed to test the
clinical implication of our ﬁndings, and the accepted thresholds for diagnosing
sodium depletion.
243 “My child tastes salty”: children’s and parents’ understanding of
salt losses in cystic ﬁbrosis
C. Marks1, S. Sharp1, K. Chetty2, C. Warde2, P. Seddon2. 1Brighton and Sussex
Medical School, Child Health, Brighton, United Kingdom; 2Royal Alexandra
Children’s Hospital, Brighton, United Kingdom
Background: Sweat salt losses are an intrinsic feature of cystic ﬁbrosis (CF),
especially with high environmental temperature, exertion or intercurrent illness.
Despite this, guidance regarding when and how to supplement salt is often patchy
and inconsistent. We explored children’s and parents understanding of salt losses in
CF and the actions they take to prevent sodium depletion.
Method: Questionnaires were given to 23 parents of children attending a paediatric
CF clinic, and to their children if aged 11 years (n = 10) to assess knowledge of
salt losses, scenarios in which salt intake should be increased and preferred methods
of salt supplementation.
Results: Responses were received from 100% of parents and 90% of children.
53% of respondents were aware that children with CF lose more salt than those
without. 74% of parents and 89% of children would increase salt intake if on holiday
in a hot climate, however only 36% of parents and 13% of children would increase
salt intake if sweating with exercise. Given choices for salt supplementation, among
parents 22% chose table salt, 52% salt tablets and 26% salt solution; among children
22% chose table salt, 56% tablets and 0% salt solution. 91% of respondents would
like more information about salt in CF.
Conclusions: Our ﬁndings show a lack of understanding of the importance of
adequate salt intake in children with CF and their parents, especially when
exercising. Education on salt intake is needed, particularly in the light of general
health messages promoting low salt intake.
